Item:Q21913: Difference between revisions

@@ aliases / en / 0 / aliases / en / 0 @@
+(22E,24S)-24-methylcholesta-5,7,22-trien-3beta-ol
@@ aliases / en / 1 / aliases / en / 1 @@
+Ergosta-5,7,22-trien-3beta-ol
@@ aliases / en / 2 / aliases / en / 2 @@
+(3S,9S,10R,13R,14R,17R)-10,13-dimethyl-17-[(E,1R,4R)-1,4,5-trimethylhex-2-enyl]-2,3,4,9,11,12,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-ol
@@ aliases / en / 3 / aliases / en / 3 @@
+(3S,9S,10R,13R,14R,17R)-17-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-10,13-dimethyl-2,3,4,9,11,12,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-ol
@@ aliases / en / 4 / aliases / en / 4 @@
+R-Methylcholesta-5,7,22E-trien-3b-ol
@@ aliases / en / 5 / aliases / en / 5 @@
+(24R)-Ergosta-5,7,22-trien-3b-ol
@@ aliases / en / 6 / aliases / en / 6 @@
+-Methylcholesta-5,7,22-trien-3b-ol
@@ aliases / en / 7 / aliases / en / 7 @@
+R-Methylcholesta-5,7,22E-trien-3beta-ol
@@ aliases / en / 8 / aliases / en / 8 @@
+(3beta,2E)-Ergosta-5,7,22-trien-3-ol
@@ aliases / en / 9 / aliases / en / 9 @@
+a-Methyl-22E-dehydrocholesterol
@@ aliases / en / 10 / aliases / en / 10 @@
+Provitamine D2
@@ aliases / en / 11 / aliases / en / 11 @@
+Ergosta-5,7,22-trien-3-ol
@@ aliases / en / 12 / aliases / en / 12 @@
+(2R,5S,15R)-14-[(2R,3E,5R)-5,6-dimethylhept-3-en-2-yl]-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-7,9-dien-5-ol
@@ aliases / en / 13 / aliases / en / 13 @@
+(3beta,22E)-Ergosta-5,7,22-trien-3-ol
@@ aliases / en / 14 / aliases / en / 14 @@
+(3beta)-Ergosta-5,7,22-trien-3-ol
@@ aliases / en / 15 / aliases / en / 15 @@
+(22E)-Ergosta-5,7,22-trien-3-ol
@@ aliases / en / 16 / aliases / en / 16 @@
+alpha-Methyl-22E-dehydrocholestero
@@ aliases / en / 17 / aliases / en / 17 @@
+-Methylcholesta-5,7,22-trien-3beta-ol
@@ aliases / en / 18 / aliases / en / 18 @@
+Provitamin D2
@@ aliases / en / 19 / aliases / en / 19 @@
+Ergosterol
@@ aliases / en / 20 / aliases / en / 20 @@
+(22E,24S)-24-methylcholesta-5,7,22-trien-3β-ol
@@ aliases / en / 21 / aliases / en / 21 @@
-(22E,24S)-24-methylcholesta-5,7,22-trien-3beta-olErgosta-5,7,22-trien-3beta-ol
@@ Property / instance of @@
+type of chemical entity
@@ Property / instance of: type of chemical entity / rank @@
+Normal rank
@@ Property / subclass of @@
+ergostane steroid
@@ Property / subclass of: ergostane steroid / rank @@
+Normal rank
@@ Property / part of @@
+ergosterol biosynthetic process
@@ Property / part of: ergosterol biosynthetic process / rank @@
+Normal rank
@@ Property / part of: ergosterol biosynthetic process / qualifier @@
+subject has role: product
@@ Property / part of @@
+ergosterol metabolic process
@@ Property / part of: ergosterol metabolic process / rank @@
+Normal rank
@@ Property / part of: ergosterol metabolic process / qualifier @@
+subject has role: participant
@@ Property / part of @@
+cellular response to ergosterol
@@ Property / part of: cellular response to ergosterol / rank @@
+Normal rank
@@ Property / part of: cellular response to ergosterol / qualifier @@
+subject has role: reactant
@@ Property / part of @@
+delta24(24-1) sterol reductase activity
@@ Property / part of: delta24(24-1) sterol reductase activity / rank @@
+Normal rank
@@ Property / part of @@
+-alpha-hydroxysteroid dehydratase activity
@@ Property / part of: 5-alpha-hydroxysteroid dehydratase activity / rank @@
+Normal rank
@@ Property / part of @@
+ergosterol UDP-glucosyltransferase activity
@@ Property / part of: ergosterol UDP-glucosyltransferase activity / rank @@
+Normal rank
@@ Property / chemical structure @@
+Ergosterol structure.svg
@@ Property / chemical structure: Ergosterol structure.svg / rank @@
+Normal rank
@@ Property / chemical structure @@
+Ergosterol.svg
@@ Property / chemical structure: Ergosterol.svg / rank @@
+Normal rank
@@ Property / chemical formula @@
+C₂₈H₄₄O
@@ Property / chemical formula: C₂₈H₄₄O / rank @@
+Normal rank
@@ Property / medical condition treated @@
+hypoparathyroidism
@@ Property / medical condition treated: hypoparathyroidism / rank @@
+Normal rank
@@ Property / medical condition treated: hypoparathyroidism / qualifier @@
+start time: 18 May 2009Timestamp +2009-05-18T00:00:00Z
Timezone +00:00
Calendar Gregorian
Precision 1 day
Before 0
After 0
-Timestamp
++2009-05-18T00:00:00Z
-Timezone
++00:00
-Calendar
+Gregorian
-Precision
+day
 Before
 After
@@ Property / medical condition treated: hypoparathyroidism / qualifier @@
+approved by: Food and Drug Administration
@@ Property / medical condition treated @@
+familial hypophosphatemia
@@ Property / medical condition treated: familial hypophosphatemia / rank @@
+Normal rank
@@ Property / medical condition treated: familial hypophosphatemia / qualifier @@
+start time: 18 May 2009Timestamp +2009-05-18T00:00:00Z
Timezone +00:00
Calendar Gregorian
Precision 1 day
Before 0
After 0
-Timestamp
++2009-05-18T00:00:00Z
-Timezone
++00:00
-Calendar
+Gregorian
-Precision
+day
 Before
 After
@@ Property / medical condition treated: familial hypophosphatemia / qualifier @@
+approved by: Food and Drug Administration
@@ Property / subject has role @@
+provitamin
@@ Property / subject has role: provitamin / rank @@
+Normal rank
@@ Property / Commons category @@
+Ergosterol
@@ Property / Commons category: Ergosterol / rank @@
+Normal rank
@@ links / en / name / links / en / name @@
+Ergosterol